Skip to contentpdufa.bio

Eli Lilly: 4 Complete Response Letters

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

The FDA's CRL release (openFDA transparency/crl, last updated 2026-11-18; snapshot read 2026-11-21) holds 4 Complete Response Letters to this company, dated 2021 to 2023, on 4 applications. The FDA releases letters selectively, so this may not be every letter the company received. Printed in the release as: Eli Lilly and Company (4).

Grouped on the company name as openFDA prints it, with capitalization, accents, punctuation and corporate-form words (Inc., LLC, Ltd., Limited, Corp., SA, USA and the like) ignored; each row shows the name as printed. A misspelled name forms its own group, and a letter printed with a heading or a bare corporate-form word where the name should be is on no company page, so a count here can be lower than the letters the release holds for a company. Facts only: no view on any outcome.

Letter dateApplicationName as printedopenFDA statusOrange Book approval after the letterSections the letter names
September 28, 2023BLA 761306Eli Lilly and CompanyApprovednot in the Orange Book (a BLA)none read
March 30, 2023BLA 761279Eli Lilly and CompanyApprovednot in the Orange Book (a BLA)none read
January 18, 2023BLA 761248Eli Lilly and CompanyApprovednot in the Orange Book (a BLA)none read
December 17, 2021BLA 761215/Original 2, BLA 761215Eli Lilly and CompanyApprovednot in the Orange Book (a BLA)none read

How each column is made: the letter date and the PDF are the FDA's release; "openFDA status" is openFDA's approval_status field as released; "Orange Book approval" is the earliest approval date the FDA's Orange Book products file (FDA files dated 2026-11-13) lists for the NDA, shown when it falls after the letter date and the letter is not on a supplement; BLAs are not in the Orange Book, so no date is shown for them; "sections" are the letter's own deficiency headings read from its PDF text layer, for letters dated 2024 or later whose PDF holds no other letter from the release ("none read" otherwise, or where no heading could be read).

Every company in the release · facts from all released CRLs · every released letter